Weight-loss drug investments: why 2025 could be a game-changer

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped Novo Nordisk A/S (CPH: NOVO-B) become the Europe’s largest company by market cap and…